Company intelligence / Profile preview

Wuyuan Capital

China

Ownership: Private
Development stage: Other

Overview

Wuyuan Capital is a China‑based venture capital/private equity investment firm that invests across technology and healthcare/biotech companies but is not itself a biotech or healthcare product company.[3][5][7][11][12]

Industry: Investors

Partnerships

Participated as an investor alongside AstraZeneca’s China investment fund, Yunfeng Fund, Cambridge Capital and SDIC China Merchants in Axbio’s $100M series B round.[5]Participated in Xbiome’s $100M series B round together with Legend Capital, Gaorong Capital, 5Y Capital, Primavera Capital Group, Chunhua HIKE Capital and Tiantu Capital.[3]

Beyond the preview

Go deeper on Wuyuan Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wuyuan Capital.

Explore the full profile